Oxford BioMedica has entered into a process development collaboration agreement with the UK Cystic Fibrosis Gene Therapy Consortium (GTC) and Imperial Innovations to develop a long-term therapy for patients with cystic fibrosis (CF). Concurrently with this, a separate option and license agreement has been signed between Oxford BioMedica and Boehringer Ingelheim. The collaboration will use a novel, replication deficient lentiviral vector, in an inhaled formulation, to selectively introduce a C...